Who Paid My Doc
Mohamed Kattih
Rancho Cucamonga, CA Medical Doctor
NPI 1104833383 CMS profile 4519
10841 White Oak Ave Ste 100, Rancho Cucamonga, CA 91730
General payments
$2,087
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mohamed Kattih of Rancho Cucamonga, CA is reported in the CMS Open Payments database as having received $2,087 across 27 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30 | 1 | |
| 2022 | General | $1,512 | 15 | |
| 2021 | General | $427 | 6 | |
| 2020 | General | $117 | 5 |
Beside peers
- Mohamed Kattih
- California median
- Middle half of California
- National median
In program year 2025, general payments to Mohamed Kattih were reported at $30. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Mohamed Kattih | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $161 | $50–$652 | $163 |
| 2020 | $117 | $114 | $34–$392 | $114 |
| 2021 | $427 | $137 | $41–$509 | $132 |
| 2022 | $1,512 | $152 | $48–$573 | $149 |
| 2023 | $0 | $162 | $50–$581 | $160 |
| 2024 | $0 | $162 | $52–$583 | $164 |
| 2025 | $30 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
1,502
Drug cost
$34,160
Branded share of claims
25%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtampza Er Oxycodone Myristate | Brand | 17 | $9,230 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 232 | $5,256 | |
| Oxycontin Oxycodone Hcl | Brand | 12 | $3,763 | |
| Gabapentin | Generic | 421 | $3,467 | |
| Diclofenac Sodium | Generic | 20 | $3,292 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 67 | $2,726 | |
| Baclofen | Generic | 128 | $1,708 | |
| Pregabalin | Generic | 86 | $1,220 | |
| Methocarbamol | Generic | 93 | $552 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 47 | $512 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$76,502
Medicare patients
86
Services billed
5,279
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 44% | |
| Depression | 35% | |
| Chronic kidney disease | 27% | |
| COPD | 26% | |
| Osteoporosis | 23% | |
| Ischemic heart disease | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 34 | 4,342 | $440 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 14 | 14 | $100 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 21 | 28 | $3 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
27 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.